Relevance of Gastrointestinal Symptoms and Blood Loss after Long Term Treatment with a Salicylate-Paracetamol Ester, A New Anti-Inflammatory Agent (BENORYLATE)

Rheumatology ◽  
1973 ◽  
Vol XII (suppl) ◽  
pp. 66-71 ◽  
Author(s):  
P. Reizenstein ◽  
A. Doberl ◽  
W. Eriksson
Keyword(s):  
Blood Loss ◽  
Gastrointestinal Symptoms ◽  
Term Treatment ◽  
Inflammatory Agent ◽  
Long Term Treatment ◽  
Anti Inflammatory

Which preparation of aspirin?

1978 ◽  
Vol 16 (13) ◽  
pp. 51-52
Keyword(s):  
Rheumatoid Arthritis ◽  
Influenza A ◽  
Term Treatment ◽  
Duration Of Treatment ◽  
First Choice ◽  
Long Term Treatment ◽  
Anti Inflammatory ◽  
Inflammatory Effect

Aspirin is often used to treat complaints expected to be transient, such as toothache, headache and influenza. A rapid analgesic and sometimes anti-pyretic effect is required, and duration of treatment is likely to be short. Aspirin is often considered the first-choice drug for rheumatic disorders, particularly rheumatoid arthritis;1 here the circumstances are quite different because long-term treatment is required at the relatively high dosage necessary to obtain an anti-inflammatory effect.2

The Pathogenesis and Therapeutic Option of Encapsulating Peritoneal Sclerosis

2005 ◽  
Vol 28 (2) ◽  
pp. 150-155 ◽  
Author(s):  
H. Kawanishi
Keyword(s):  
Therapeutic Option ◽  
Gastrointestinal Symptoms ◽  
Term Treatment ◽  
Disease Stage ◽  
Fatal Complication ◽  
Appropriate Treatment ◽  
Long Term Treatment ◽  
Negative Effect ◽  
Substantial Risk

Since the first peritoneal dialysis (PD) patients with encapsulating peritoneal sclerosis (EPS) were reported in 1980, EPS has been considered primarily a fatal complication. The incidence of EPS in PD patients has been reported to be from 0.7% to 7.3%, and the rate appears to be higher in patients receiving long-term treatment. Most data from Japan has shown an overall incidence of 2.5% with an evident negative effect of increasing duration of PD, which also augments mortality. Since EPS occurred after withdrawal from PD in more than half of the patients, strict monitoring is necessary when a long-term PD patient is withdrawn from PD. Maintaining patients on standard PD for more than 8 years using conventional solutions is associated with a substantial risk for development of EPS. Appropriate treatment according to the disease stage is most important in EPS treatment. Therefore, when examining a PD patient complaining of gastrointestinal symptoms, the possibility of EPS has to be kept in mind. Basic therapeutic tactics for EPS include an appropriate use of steroids. If the state of bowel obstruction persists, laparotomy and enterolysis should be performed to obtain complete cure. It is now recognized that EPS is not a fatal complication of PD.

EVALUATION OF COMPLEMENTARY EFFECTS OF TURMERIC, GINGER AND CINNAMON WITH ASPIRIN

INDIAN DRUGS ◽  
2018 ◽  
Vol 55 (07) ◽  
pp. 28-35
Author(s):  
T. K. Mohapatra ◽  
P Sarkar ◽  
R. N Dash ◽  
A. K Moharana ◽  
B. B. Subudhi
Keyword(s):  
Analgesic Effect ◽  
Term Treatment ◽  
Positive Interaction ◽  
Inflammatory Disorders ◽  
Stomach Mucosa ◽  
Long Term Treatment ◽  
Growing Body ◽  
Anti Inflammatory ◽  
Inflammatory Effect

Aspirin (ASA) has been utilized against many inflammatory disorders. In recent years a growing body of research also suggests its efficacy against cancer. The use of ASA in these conditions requires long-term treatment. However, gastro-toxicity associated with ASA is a major challenge. Household species including turmeric, ginger, and cinnamon have enjoyed medicinal values including gastroprotective properties. Accordingly, their co-use with ASA may be beneficial in ensuring a safe long-term treatment. With this objective, the study was undertaken which revealed encouraging effects. A positive interaction was found with analgesic effect and anti-inflammatory effect of ASA. Further, these spices were shown to prevent gastro toxicity of ASA. In conclusion, ginger and turmeric can be used to complement the use of ASA against inflammatory disorders without the deleterious effects on stomach mucosa.

A Controlled Clinical Trial of a New Anti-Inflammatory Drug, Diftalone, in Rheumatoid Arthritis

1974 ◽  
Vol 2 (5) ◽  
pp. 338-346 ◽  
Author(s):  
Valentin Stroescu ◽  
Carmen Georgescu ◽  
Radu Voiosu
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Trial ◽  
Randomized Trial ◽  
Term Treatment ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Inflammatory Drug ◽  
Long Term Treatment ◽  
Anti Inflammatory

In a double-blind, randomized trial on thirty-two patients affected by classical or definite rheumatoid arthritis, we have tried the effectiveness and safety of 500 mg/day oral diftalone versus 75 mg/day oral indomethacin for a period of six to twelve months treatment. Diftalone proved to be an effective and well tolerated anti-inflammatory drug in long-term treatment of rheumatoid arthritis. Its activity and safety is at least comparable to that achieved by the use of indomethacin.

scholarly journals HYALURONIC ACID PREPARATIONS IN BIG JOINT OSTEOARTHRITIS MANAGEMENT

2021 ◽  
pp. 80-96
Author(s):  
O. V. Kalashnikov ◽  
O. M. Sulyma ◽  
T. I. Osadchuk ◽  
А. V. Kalashnikov ◽  
V. B. Zayets ◽  
...  
Keyword(s):  
Side Effects ◽  
Term Treatment ◽  
Safety Level ◽  
Orthopedic Surgeons ◽  
Effi Ciency ◽  
Long Term Treatment ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
And Function

Abstract. The authors of the paper analyzed the experience of domestic and foreign experts on the effi-ciency of HA preparation in big joint osteoarthritis management. Task of the study is to analyze literature sources to identify the efficiency of HA preparations in big joints osteoarthritis management. Materials and methods: articles published by specialized scientific journals, paper collections, internet sources. Results: The analysis of literature sources determined the essential role of HA in joint cartilage nutrition and function. The researches tend to believe that an ideal HA preparation must be as close as possible to the physiological HA of joint’s synovial fluid. The HA preparation elaborated in our state, Artropatch meets these demands completely. Conclusions. Modern HA injectable preparations are expedient on the 1-3 stage of OA. Anti-inflammatory effect of HA preparations predetermines the possibility to decrease the intake dose and period of non-steroid anti-inflammatory drugs, consequently decreasing the risk of many unfavorable side effects of NSAIPs. The high safety level of HA preparations and no significant side effects after long-term treatment make them widely used in clinical practice of modern orthopedic surgeons.

Long-Term Tolerability Study of Voltaren

1975 ◽  
Vol 3 (3) ◽  
pp. 145-152 ◽  
Author(s):  
T Miura
Keyword(s):  
Serum Proteins ◽  
Term Treatment ◽  
Total Serum ◽  
Term Therapy ◽  
Analgesic Agent ◽  
Long Term Treatment ◽  
Term Tolerability ◽  
Anti Inflammatory ◽  
Pre Treatment

Clinical and laboratory examinations were conducted in order to assess the long-term tolerability of Voltaren, a new anti-inflammatory and analgesic agent. Pre-treatment, repeated on-treatment and after-treatment investigations of haemoglobin, erythrocyte count, total and differential leucocyte count, platelet count, SGOT, SGPT, alkaline phosphatase, total serum proteins and urinary protein and sugar were conducted in 13 patients. The period of treatment with Voltaren was 110 to 559 days. In all these tests, there were no unwanted effects attributable to long-term treatment with Voltaren. Our study would indicate that Voltaren is a safe drug which has no effect on the organs of haemopoiesis, nor on hepatic or renal function, even in long-term therapy. Therefore, Voltaren can be used as an anti-inflammatory and analgesic agent not only in short-term therapy but also in the long-term treatment of chronic diseases.

Cisapride in the Long-Term Treatment of Chronic Gastroparesis: A 2-Year Open-Label Study

1997 ◽  
Vol 25 (4) ◽  
pp. 182-189 ◽  
Author(s):  
BJ Kendall ◽  
ET Kendall ◽  
I Soykan ◽  
RW McCallum
Keyword(s):  
Gastric Emptying ◽  
Symptom Score ◽  
Gastrointestinal Symptoms ◽  
Symptomatic Improvement ◽  
Term Treatment ◽  
Open Label ◽  
Open Label Study ◽  
Long Term Treatment

The effect of long-term cisapride therapy (20 mg orally three times daily for 2 years) on gastric emptying and gastrointestinal symptoms was investigated in 30 patients with severe gastroparesis (24 idiopathic, 6 diabetic). Symptoms were assessed every 2 months, using an overall symptom score based on six symptoms (anorexia, nausea, vomiting, pain, early satiety and bloating), and a 2-year mean overall symptom score was used for analysis. Gastric emptying was measured at 0, 6, 12, 18 and 24 months. Of the 24 patients who completed the study, 10 showed a significant improvement in gastric emptying ( P < 0.05) and felt improved on therapy, seven patients showing a > 20% improvement in overall symptom score compared to baseline. Results for 15 patients who underwent at least one follow-up gastric-emptying test showed only a weak correlation between individual symptom score and gastric emptying ( r = 0.40). Thus long-term cisapride therapy at the study dose produced long-term symptomatic improvement in 42% of patients with severe gastroparesis, with sustained acceleration of gastric emptying for up to 2 years.

Sign in / Sign up

Export Citation Format

Share Document